Badanie ACCOMPLISH – kolejny argument za nowoczesną terapią skojarzoną w nadciśnieniu tętniczym (Avoiding Cardiovascular Events through COMbination therapy in Patients LIving with Systolic Hypertension) Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2008
Słowa kluczowe:
nadciśnienie tętnicze, amlodypina, benazepril, ACCOMPLISH
##plugins.themes.bootstrap3.article.main##
Abstrakt
Nadciśnienie tętnicze jest jednym z najczęściej występujących problemów kardiologicznych, z jakimi mamy do czynienia w praktyce klinicznej. Odsetek skutecznie leczonych pacjentów jest niski. W poniższym opracowaniu przedstawiamy wyniki badania ACCOMPLISH, w którym skojarzona terapia hipotensyjna amlodypina+benazepril okazała się skuteczniejsza w zapobieganiu niekorzystnym incydentom sercowo-naczyniowym niż terapia benazepril+hydrochlorotiazyd.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Folga, A., & Mamcarz , A. (2008). Badanie ACCOMPLISH – kolejny argument za nowoczesną terapią skojarzoną w nadciśnieniu tętniczym (Avoiding Cardiovascular Events through COMbination therapy in Patients LIving with Systolic Hypertension). Medycyna Faktów , 1(1(1), 29-36. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/1803
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Zdrojewski T., Wyrzykowski B., Szczech R. at al (Steering Committees of the Programmes NATPOL PLUS; SMS; The Polish 400- Cities Project): Epidemiology and prevention of arterial hypertension in Poland. Blood Press. Suppl. 2005; 2: 10-16.
2. Zdrojewski T., Szpakowski P., Bandosz P. et al.: Arterial hypertension in Poland in 2002. J. Hum. Hypertens. 2004; 18(8): 557-562.
3. Kannel W.B.: Risk stratification in hypertension: new insights from the Framingham Study. Am. J. Hypertens. 2000; 13(1 Pt 2): 3S-10S.
4. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2007; 28(12): 1462-1536.
5. Jamerson K.A., Bakris G.L., Wun C.: Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial. The first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am. J. Hypertens. 2004; 17: 793-801.
6. Weber M.A., Bakris G.L., Dahlof B. et al.: Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007; 16(1): 13-19.
7. Jamerson K., Bakris G.L., Dahlof B. et al.: ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007; 16(2): 80-86.
8. Weber M.A., Julius S., Kjeldsen S.E. et al.: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363(9426): 2049-2051.
9. Dahlof B., Sever P.S., Poulter N.R. et al. (ASCOT Investigators): Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997.
11. Dahlof B., Devereux R.B., Kjeldsen S.E. et al. (LIFE Study Group): Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 995-1003.
12. Lindholm L.H., Carlberg B., Samuelsson O.: Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366(9496): 1545-1553.
2. Zdrojewski T., Szpakowski P., Bandosz P. et al.: Arterial hypertension in Poland in 2002. J. Hum. Hypertens. 2004; 18(8): 557-562.
3. Kannel W.B.: Risk stratification in hypertension: new insights from the Framingham Study. Am. J. Hypertens. 2000; 13(1 Pt 2): 3S-10S.
4. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2007; 28(12): 1462-1536.
5. Jamerson K.A., Bakris G.L., Wun C.: Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial. The first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am. J. Hypertens. 2004; 17: 793-801.
6. Weber M.A., Bakris G.L., Dahlof B. et al.: Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007; 16(1): 13-19.
7. Jamerson K., Bakris G.L., Dahlof B. et al.: ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007; 16(2): 80-86.
8. Weber M.A., Julius S., Kjeldsen S.E. et al.: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363(9426): 2049-2051.
9. Dahlof B., Sever P.S., Poulter N.R. et al. (ASCOT Investigators): Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997.
11. Dahlof B., Devereux R.B., Kjeldsen S.E. et al. (LIFE Study Group): Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 995-1003.
12. Lindholm L.H., Carlberg B., Samuelsson O.: Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366(9496): 1545-1553.